Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling
Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, w...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2019-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/8/5/442 |
| _version_ | 1797709193709355008 |
|---|---|
| author | Ana Raquel-Cunha Diana Cardoso-Carneiro Rui M. Reis Olga Martinho |
| author_facet | Ana Raquel-Cunha Diana Cardoso-Carneiro Rui M. Reis Olga Martinho |
| author_sort | Ana Raquel-Cunha |
| collection | DOAJ |
| description | Lung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations„. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed. |
| first_indexed | 2024-03-12T06:32:49Z |
| format | Article |
| id | doaj.art-3b0bb8904c3b4e41bf86cf4dbf976da1 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-12T06:32:49Z |
| publishDate | 2019-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-3b0bb8904c3b4e41bf86cf4dbf976da12023-09-03T01:28:28ZengMDPI AGCells2073-44092019-05-018544210.3390/cells8050442cells8050442Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK SignalingAna Raquel-Cunha0Diana Cardoso-Carneiro1Rui M. Reis2Olga Martinho3Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, PortugalLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, PortugalLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, PortugalLife and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, PortugalLung cancer is the most deadly neoplasm with the highest incidence in both genders, with non-small cell lung cancer (NSCLC) being the most frequent subtype. Somatic mutations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene are key drivers of NSCLC progression, with EGFR inhibitors being particularly beneficial for patients carrying the so-called “EGFR-sensitizing mutations„. However, patients eventually acquire resistance to these EGFR inhibitors, and a better knowledge of other driven and targetable proteins will allow the design of increasingly accurate drugs against patients’ specific molecular aberrations. Raf kinase inhibitory protein (RKIP) is an important modulator of relevant intracellular signaling pathways, including those controlled by EGFR, such as MAPK. It has been reported that it has metastasis suppressor activity and a prognostic role in several solid tumors, including lung cancer. In the present review, the potential use of RKIP in the clinic as a prognostic biomarker and predictor of therapy response in lung cancer is addressed.https://www.mdpi.com/2073-4409/8/5/442lung cancerEGFRRKIP signalingprognosiscancer therapy |
| spellingShingle | Ana Raquel-Cunha Diana Cardoso-Carneiro Rui M. Reis Olga Martinho Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling Cells lung cancer EGFR RKIP signaling prognosis cancer therapy |
| title | Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling |
| title_full | Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling |
| title_fullStr | Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling |
| title_full_unstemmed | Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling |
| title_short | Current Status of Raf Kinase Inhibitor Protein (RKIP) in Lung Cancer: Behind RTK Signaling |
| title_sort | current status of raf kinase inhibitor protein rkip in lung cancer behind rtk signaling |
| topic | lung cancer EGFR RKIP signaling prognosis cancer therapy |
| url | https://www.mdpi.com/2073-4409/8/5/442 |
| work_keys_str_mv | AT anaraquelcunha currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling AT dianacardosocarneiro currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling AT ruimreis currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling AT olgamartinho currentstatusofrafkinaseinhibitorproteinrkipinlungcancerbehindrtksignaling |